eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
5/2024
vol. 41
 
Share:
Send email
Share:
abstract:
Original paper

Is there a correlation between serum and faecal calprotectin levels and the disease severity in patients with moderate-to-severe plaque psoriasis? A pilot study

Karina Polak
1, 2
,
Tomasz Muszyński
3, 4
,
Aleksandra Frątczak 
1
,
Bartosz Miziołek
1
,
Beata Bergler-Czop
1

  1. Chair and Department of Dermatology, Medical University of Silesia, Katowice, Poland
  2. Doctoral School of the Medical University of Silesia, Katowice, Poland
  3. Brothers Hospitallers of Saint John of God Hospital, Krakow, Poland
  4. Doctoral School of Medical and Health Sciences, Jagiellonian University, Krakow, Poland
Adv Dermatol Allergol 2024; XLI (5): 487-494
DOI: https://doi.org/10.5114/ada.2024.142576
Online publish date: 2024/08/28
View full text Get citation
 
Introduction:
The role of calprotectin in psoriasis still remains unclear.

Aim:
To elucidate the associations between the concentrations of serum and faecal calprotectin (CP) and the severity of psoriasis in 20 patients with moderate-to-severe plaque psoriasis and 20 healthy individuals.

Material and methods:
The CP levels as well as the disease severity including Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA) score and Dermatology Life Quality Index (DLQI) were assessed.

Results:
The median serum CP level in the psoriasis group was notably higher at 112.24 µg/l (interquartile range, IQR: 81.39–206.82 µg/l) compared to 60.31 µg/l (IQR: 37.41–81.54 µg/l) in the control group (p = 0.001), while the median faecal CP levels were similar between the two groups: 15.00 µg/g (IQR: 6.20–36.13 µg/g) in psoriasis patients and 13.00 µg/g (IQR: 10.26–30.15 µg/g) in controls (p = 0.766). No significant correlations between serum and faecal CP level and the PASI, BSA and DLQI were found.

Conclusions:
Despite the fact that patients with moderate-to-severe plaque psoriasis seem to present general higher blood calprotectin levels than healthy individuals, they are still within the population cut-off value. The elevated blood calprotectin levels are not conclusively linked to increased severity of psoriasis or to the deterioration in quality of life. Also, in individuals with psoriasis, gastrointestinal inflammation does not differ markedly from healthy controls.

keywords:

serum calprotectin, faecal calprotectin, psoriasis
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.